National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom

Bakhai, Ameet, Flather, Marcus D., Collinson, Julian R., Stevens, Warren, Normand, Charles, Alemao, Evo, Itzler, Robbin and Ben-Joseph, Rami (2003) National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom. International Journal of Cardiology, 91 (2-3). pp. 163-172. ISSN 0167-5273

Full text not available from this repository. (Request a copy)

Abstract

Acute coronary syndromes without ST elevation are a major health and economic burden. Treatments such as glycoprotein IIb/IIIa antagonists like tirofiban reduce the risk of complications but the cost impact of these agents including cost offsets of avoiding complications are needed particularly in Europe.

Item Type:	Article
Uncontrolled Keywords:	aged,angina, unstable,anticoagulants,cardiac catheterization,coronary angiography,coronary disease,electrocardiography,female,great britain,hemorrhage,heparin,humans,male,middle aged,myocardial infarction,patient admission,platelet aggregation inhibitors,platelet glycoprotein gpiib-iiia complex,predictive value of tests,prospective studies,risk factors,sensitivity and specificity,syndrome,treatment outcome,tyrosine
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	20 Jan 2014 16:16
Last Modified:	17 Aug 2023 14:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/46302
DOI:	10.1016/S0167-5273(03)00023-8

Actions (login required)

View Item